Serpine 1 induces alveolar type II cell senescence through activating p53-p21-Rb pathway in fibrotic lung disease

Aging Cell

Volumn 16, Issue 5, 2017, Pages 1114-1124

  Jiang, Chunsun ^a   Liu, Gang ^a   Luckhardt, Tracy ^a   Antony, Veena ^a   Zhou, Yong ^a   Carter, A Brent ^a   Thannickal, Victor J ^a   Liu, Rui Ming ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

aging; lung fibrosis; p53; serpin 1; type 2 alveolar epithelial cell senescence

Indexed keywords

BETA GALACTOSIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P16; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; SERPINE 1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; BLEOMYCIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOXORUBICIN; SMALL INTERFERING RNA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; BRONCHOALVEOLAR LAVAGE FLUID; COMPARATIVE STUDY; CONTROLLED STUDY; DOXORUBICIN INDUCED PULMONARY FIBROSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SILENCING; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; L2 CELL LINE; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; RAT; SENESCENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; AGING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL AGING; CELL LINE; DEFICIENCY; DISEASE MODEL; DRUG EFFECT; FIBROSING ALVEOLITIS; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; LUNG; LUNG ALVEOLUS EPITHELIUM CELL; MALE; METABOLISM; PATHOLOGY;

AGING; ALVEOLAR EPITHELIAL CELLS; ANIMALS; BLEOMYCIN; CELL LINE; CELLULAR SENESCENCE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE MODELS, ANIMAL; DOXORUBICIN; GENE EXPRESSION REGULATION; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MICE; MICE, KNOCKOUT; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RETINOBLASTOMA PROTEIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85029305513     PISSN: 14749718     EISSN: 14749726     Source Type: Journal    
DOI: 10.1111/acel.12643     Document Type: Article

References (44)

1. Akram KM, Lomas NJ, Forsyth NR, Spiteri MA (2014) Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53. Int. J. Clin. Exp. Pathol. 7, 552–564.
2. Aoshiba K, Tsuji T, Nagai A (2003) Bleomycin induces cellular senescence in alveolar epithelial cells. Eur. Respir. J. 22, 436–443.
3. Aoshiba K, Tsuji T, Kameyama S, Itoh M, Semba S, Yamaguchi K, Nakamura H (2013) Senescence-associated secretory phenotype in a mouse model of bleomycin-induced lung injury. Exp. Toxicol. Pathol. 65, 1053–1062.
4. Barkauskas CE, Noble PW (2014) Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis. Am. J. Physiol. Cell Physiol. 306, C987–C996.
5. Bhandary YP, Shetty SK, Marudamuthu AS, Ji HL, Neuenschwander PF, Boggaram V, Morris GF, Fu J, Idell S, Shetty S (2013) Regulation of lung injury and fibrosis by p53-mediated changes in urokinase and plasminogen activator inhibitor-1. Am. J. Pathol. 183, 131–143.
6. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377, 646–649.
7. Chang W, Wei K, Jacobs SS, Upadhyay D, Weill D, Rosen GD (2010) Sparc suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. J. Biol. Chem. 285, 8196–8206.
8. Chao CC (2015) Mechanisms of p53 degradation. Clin. Chim. Acta 438, 139–147.
9. Childs BG, Durik M, Baker DJ, van Deursen JM (2015) Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat. Med. 21, 1424–1435.
10. Chilosi M, Carloni A, Rossi A, Poletti V (2013) Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Transl. Res. 162, 156–173.
11. Citrin DE, Shankavaram U, Horton JA, Shield W III, Zhao S, Asano H, White A, Sowers A, Thetford A, Chung EJ (2013) Role of type II pneumocyte senescence in radiation-induced lung fibrosis. J. Natl Cancer Inst. 105, 1474–1484.
12. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, Campisi J. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367.
13. Disayabutr S, Kim EK, Cha SI, Green G, Naikawadi RP, Jones KD, Golden JA, Schroeder A, Matthay MA, Kukreja J, Erle DJ, Collard HR, Wolters PJ (2016) Mir-34 mirnas regulate cellular senescence in type II alveolar epithelial cells of patients with idiopathic pulmonary fibrosis. PLoS ONE 11, e0158367.
14. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B (1992) Definition of a consensus binding site for p53. Nat. Genet. 1, 45–49.
15. Elzi DJ, Lai Y, Song M, Hakala K, Weintraub ST, Shiio Y (2012) Plasminogen activator inhibitor 1–insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence. Proc. Natl Acad. Sci. USA 109, 12052–12057.
16. Eren M, Boe AE, Klyachko EA, Vaughan DE (2014a) Role of plasminogen activator inhibitor-1 in senescence and aging. Semin. Thromb. Hemost. 40, 645–651.
17. Eren M, Boe AE, Murphy SB, Place AT, Nagpal V, Morales-Nebreda L, Urich D, Quaggin SE, Budinger GR, Mutlu GM, Miyata T, Vaughan DE (2014b) Pai-1-regulated extracellular proteolysis governs senescence and survival in klotho mice. Proc. Natl Acad. Sci. USA 111, 7090–7095.
18. Fernandez Perez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, Yi ES, Ryu JH (2010) Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 137, 129–137.
19. Ghosh AK, Rai R, Park KE, Eren M, Miyata T, Wilsbacher LD, Vaughan DE (2016) A small molecule inhibitor of pai-1 protects against doxorubicin-induced cellular senescence: molecular basis. Oncotarget 7, 72443–72457.
20. Hogan BL, Barkauskas CE, Chapman HA, Epstein JA, Jain R, Hsia CC, Niklason L, Calle E, Le A, Randell SH, Rock J, Snitow M, Krummel M, Stripp BR, Vu T, White ES, Whitsett JA, Morrisey EE (2014) Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function. Cell Stem Cell 15, 123–138.
21. Huang WT, Vayalil PK, Miyata T, Hagood J, Liu RM (2012) Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis. Am. J. Respir. Cell Mol. Biol. 46, 87–95.
22. Huang WT, Akhter H, Jiang C, MacEwen M, Ding Q, Antony V, Thannickal VJ, Liu RM (2015) Plasminogen activator inhibitor 1, fibroblast apoptosis resistance, and aging-related susceptibility to lung fibrosis. Exp. Gerontol. 61, 62–75.
23. Junqueira LC, Bignolas G, Brentani RR (1979) Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem. J. 11, 447–455.
24. Kortlever RM, Higgins PJ, Bernards R (2006) Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat. Cell Biol. 8, 877–884.
25. Kunz C, Pebler S, Otte J, von der Ahe D (1995) Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res. 23, 3710–3717.
26. Leung J, Cho Y, Lockey RF, Kolliputi N (2015) The role of aging in idiopathic pulmonary fibrosis. Lung 193, 605–610.
27. Li J, Kurokawa M (2015) Regulation of MDM2 stability after DNA damage. J. Cell. Physiol. 230, 2318–2327.
28. Lijnen HR (2005) Pleiotropic functions of plasminogen activator inhibitor-1. J. Thromb. Haemost. 3, 35–45.
29. Maclaine NJ, Hupp TR (2011) How phosphorylation controls p53. Cell Cycle 10, 916–921.
30. Mark M, Thurlimann B (2012) Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission. Med. Oncol. 29, 1477–1478.
31. Marudamuthu AS, Shetty SK, Bhandary YP, Karandashova S, Thompson M, Sathish V, Florova G, Hogan TB, Pabelick CM, Prakash YS, Tsukasaki Y, Fu J, Ikebe M, Idell S, Shetty S (2015) Plasminogen activator inhibitor-1 suppresses profibrotic responses in fibroblasts from fibrotic lungs. J. Biol. Chem. 290, 9428–9441.
32. Marzec KA, Lin MZ, Martin JL, Baxter RC (2015) Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage. Oncotarget 6, 26583–26598.
33. Mohapatra A, Van Dyken SJ, Schneider C, Nussbaum JC, Liang HE, Locksley RM (2016) Group 2 innate lymphoid cells utilize the IRF4-IL-9 module to coordinate epithelial cell maintenance of lung homeostasis. Mucosal Immunol. 9, 275–286.
34. Nevadunsky NS, Mbagwu C, Mizrahi N, Burton E, Goldberg GL (2013) Pulmonary fibrosis after pegylated liposomal doxorubicin in a patient with uterine papillary serous carcinoma. J. Clin. Oncol. 31, e167–e169.
35. Osterholzer JJ, Christensen PJ, Lama V, Horowitz JC, Hattori N, Subbotina N, Cunningham A, Lin Y, Murdock BJ, Morey RE, Olszewski MA, Lawrence DA, Simon RH, Sisson TH (2011) Pai-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type ii alveolar epithelial cell injury. J. Pathol. 228, 170–180.
36. Schafer MJ, White TA, Iijima K, Haak AJ, Ligresti G, Atkinson EJ, Oberg AL, Birch J, Salmonowicz H, Zhu Y, Mazula DL, Brooks RW, Fuhrmann-Stroissnigg H, Pirtskhalava T, Prakash YS, Tchkonia T, Robbins PD, Aubry MC, Passos JF, Kirkland JL, Tschumperlin DJ, Kita H, LeBrasseur NK (2017) Cellular senescence mediates fibrotic pulmonary disease. Nat. Commun. 8, 14532.
37. Serrano-Mollar A, Nacher M, Gay-Jordi G, Closa D, Xaubet A, Bulbena O (2007) Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis. Am. J. Respir. Crit. Care Med. 176, 1261–1268.
38. Shetty S, Shetty P, Idell S, Velusamy T, Bhandary YP, Shetty RS (2008) Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. J. Biol. Chem. 283, 19570–19580.
39. Shetty SK, Bhandary YP, Marudamuthu AS, Abernathy D, Velusamy T, Starcher B, Shetty S (2012) Regulation of airway and alveolar epithelial cell apoptosis by p53-induced plasminogen activator inhibitor-1 during cigarette smoke exposure injury. Am. J. Respir. Cell Mol. Biol. 47, 474–483.
40. Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, Cunningham A, Dave A, Engelhardt JF, Liu X, White ES, Thannickal VJ, Moore BB, Christensen PJ, Simon RH (2010) Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 181, 254–263.
41. Zappa L, Savady R, Humphries GN, Sugarbaker PH (2009) Interstitial pneumonitis following intrapleural chemotherapy. World J. Surg. Oncol. 7, 17.
42. Zhang YP, Li WB, Wang WL, Liu J, Song SX, Bai LL, Hu YY, Yuan YD, Zhang M (2012) Sirna against plasminogen activator inhibitor-1 ameliorates bleomycin-induced lung fibrosis in rats. Acta Pharmacol. Sin. 33, 897–908.
43. Zhang YP, Wang WL, Liu J, Li WB, Bai LL, Yuan YD, Song SX (2013) Plasminogen activator inhibitor-1 promotes the proliferation and inhibits the apoptosis of pulmonary fibroblasts by ca(2+) signaling. Thromb. Res. 131, 64–71.
44. Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y (2009) Tumour suppression by p53: the importance of apoptosis and cellular senescence. J. Pathol. 219, 3–15.